Transduction of T cells with a chimeric immune T cell receptor (CIR) has been proposed as a strategy to generate cellular immunity against viral pathogens such as HIV-1. In the case of the CD4-CD3-chain (CD4-) CIR, specificity for HIV-1 is conferred by binding of the CD4 moiety to gp120 on the surface of infected cells. However, it is unclear whether CD4--T cells may differ from naturally derived CD8 ϩ cytotoxic T cells (CTL) in their susceptibility to viral escape mechanisms or ability to recognize different cell types that support viral replication. We demonstrate that CIR-T cells can mediate antiviral activity against HIV-1 in cells that are resistant to class I-restricted CTL-mediated activity. Furthermore, CIR-T cells can suppress virus in multiple cell types, including monocytes, dendritic cells, and lymphocyte-dendritic cell clusters. These results provide evidence that T cells can be redirected against novel targets, and that independence from the class I pathway may have distinct advantages.
Introduction
Cellular immunity has important roles in viral and tumor immunology. CD8 ϩ effector T cells, cytotoxic T lymphocytes (CTL), are capable of specifically recognizing and killing cells expressing abnormal proteins, and therefore are believed to mediate clearance of cells infected with viruses or expressing abnormal regulatory proteins leading to oncogenic transformation. The specificity of CTL is conferred by the T cell receptor (TCR), which is an immunoglobulinlike surface molecule directed against a foreign peptide presented by a major histocompatibility class I molecule on the target cell surface (reviewed in Eisen et al., 1996) . Recognition of the target cell and triggering of the CTL to kill is therefore restricted by both the presented peptide sequence and the class I allele.
Most cells express surface class I molecules, which present peptide fragments of proteins being produced within the cell for surveillance by CTL. The process of class I-mediated peptide presentation involves proteolysis of newly translated proteins by the proteasome, transportation of peptide fragments into the rough endoplasmic reticulum (RER) by the TAP complex, binding of peptides to nascent class I molecules in the RER, and presentation of the peptide-MHC complexes on the cell surface (Eisen et al., 1996) . Given the necessity of this complex pathway for recognition of infected or abnormal cells by CTL, viruses (Collins and Baltimore, 1999; Koup, 1994; Powis, 1998) and tumor cells (Costello et al., 1999; Marincola et al., 2000) have evolved mechanisms to interrupt this process.
We have demonstrated previously (Yang et al., 1997b ) that CD8 ϩ T cells transduced with a recombinant T cell receptor have potent activity against HIV-1 infected cells in vitro. This study examined T3F3 cells, which have been transduced with a chimeric T cell receptor (CIR) containing the human CD4 molecule spliced to the chain signaling domain of the CD3 complex (CD4-), rendering T3F3 cy-tolytic for HIV-1-infected cells through binding of the CIR to HIV-1 gp120 on the infected cell surface (Roberts et al., 1994) . Administration of CIR-transduced cells in vivo has been considered a potential strategy for generating virusspecific CD8 ϩ T cells, since naturally occurring MHC class I-restricted CD8 ϩ cytotoxic T lymphocytes (CTL) are believed to have an important role in the control of HIV-1 infection (reviewed in Yang and Walker, 1997) .
Because CIR-T cells interact with infected cells through a non-physiologic mechanism, it is not clear whether they have the same properties as naturally generated HIV-1specific CTL. The ability to recognize cells independently of antigen processing could be advantageous in bypassing viral escape mechanisms that modulate the class I pathway, but varying levels of gp120 expression or other factors specific to non-lymphocyte cell types could limit the activity of CIR-T cells. We therefore examine further the antiviral function of HIV-1-specific CIR-T cells.
Results

CIR-CTL perform effector functions independently of the class I pathway
Because a common mechanism of immune evasion of CTL is interference with the class I pathway, we evaluated the ability of naturally-derived HIV-1-specific CTL and CIR-CTL to suppress HIV-1 system in cells that are defective in presentation of class I antigens. Acutely HIV-1infected T1 cells, and derivative T2 cells that are deficient in TAP and therefore incapable of transporting class I antigens from the proteasome (Salter and Cresswell, 1986) , were co-cultured with an HIV-1-specific CTL clone (68A62), control CD8 ϩ T cells from an uninfected individual (T3), or CD4--transduced CIR-T cells (T3F3). As we previously observed for T1 cells (Yang et al., 1997b) , CTL and CIR-T cells, but not untransduced control cells, were inhibitory for viral replication in T1 cells by orders of magnitude ( Fig.  1A) . In contrast, 68A62 was unable to inhibit replication in the TAP-deficient cell line T2, whereas T3F3 cells remained inhibitory (Fig. 1B) .
In four independent experiments with naturally derived CTL clones (five clones recognizing A2-and B60-restricted epitopes in Gag, RT, and Nef), the clones suppressed viral replication by 2.9 Ϯ 1.1 (mean Ϯ 1 S.D.) log 10 units in T1 cells, but 0.2 Ϯ 0.3 log 10 units in T2 cells (P Ͻ 0.00001) (not shown). In two independent experiments with T3F3, viral replication was suppressed by 3.7 Ϯ 0.3 log 10 units in T1 cells and 3.0 Ϯ 0.4 log 10 units in T2 cells (P Ͼ 0.20), with the negative control T3 cells inhibiting 0.2 Ϯ 0.2 and 0.1 Ϯ 0.1 log 10 units in these cells, respectively (not shown). In sum, these results indicated that interference with the class I antigen-processing pathway ablates the antiviral activity of natural CTL, but does not affect the function of CIR-CTL.
CIR-CTL are active against a broad spectrum of primary cell types
In parallel to our previous study on whether naturally derived CTL are able to suppress viral replication in different primary cell types (Severino et al., 2000) , we examined the ability of T3F3 to suppress viral replication in primary CD4 ϩ lymphocytes, monocytes, dendritic cells, and dendritic cell/lymphocyte clusters (Fig. 2) . Monocytes ( Fig. 2B ) and dendritic cells ( Fig. 2C) were less productively infected than lymphocytes ( Fig. 2A) , and dendritic cell/lymphocyte clusters (Fig. 2D) were the most productive, as previously observed (Severino et al., 2000) . However, HIV-1 replication in all cell types was inhibited by T3F3 cells. Over four experiments for each cell type, T3F3 cells suppressed viral replication by (mean Ϯ 1 S.D.) 2.7 Ϯ 1.1 log 10 units in lymphocytes, 3.2 Ϯ 0.8 log 10 units in monocytes, 3.4 Ϯ 0.9 log 10 units in dendritic cells, and 2.5 Ϯ 2.0 log 10 units in dendritic cell-lymphocyte clusters (not shown). Suppression in the dendritic cell/lymphocyte clusters was therefore the least efficient and consistent as compared to the other cells, similar to what was previously observed for naturallyderived CTL clones (Severino et al., 2000) . These data indicated that CIR-CTL can act against several primary cell types believed to be targets for HIV-1 replication in vivo. Fig. 1 . Suppression of HIV-1 replication in T1 and T2 cells. T1 cells, or their TAP-deficient derivative T2 cells, were acutely infected with HIV-1 IIIB and cocultured with T3 (a primary CD8 ϩ T cell line from an HIV-1 seronegative donor), T3F3 (T3 transduced with the CD4-chain chimeric T cell receptor), or 68A62 (an RT-specific A2-restricted CTL clone isolated from an HIV-1-infected individual). At the indicated time intervals, HIV-1 p24 antigen was assessed. These results are representative of two experiments with T3 and T3F3, and four experiments with naturally derived CTL clones (68A62 and four others recognizing A2-and B60restricted epitopes in Gag, RT, and Nef) (data described in Results, and not shown).
Discussion
Chimeric immune receptor-transduced T cells have been proposed as a potential immunotherapeutic approach for the treatment of HIV-1 and malignancies. By using a molecule that binds a cell surface target protein (such as CD4 that can bind HIV-1 gp120, or the antigen-binding region of an immunoglobulin molecule) as the external domain of the chimeric immune receptor, the transduced cells can be selectively targeted against a cell of interest. This may allow the production of antigen-specific T cells through CIR transduction, able to recognize target cells such as HIV-1 infected T cells (Roberts et al., 1994) or tumor cells (McGuinness et al., 1999; Patel et al., 2000) .
Our data suggest that CIR-T cells may functionally differ from naturally-derived CTL yet maintain the ability to act on multiple primary different cell types. The independence of CIR-T cell activity from needing to recognize specific viral HLA-restricted epitopes may be an advantageous aspect of this approach to generating CTL. Epitope point mutations, epitope antagonism, interference with antigen processing, and class I downregulation all have been mechanisms postulated to allow avoidance of CTL responses in vivo (Collins and Baltimore, 1999; Koup, 1994; McMichael and Phillips, 1997) . Our data indicate that CIR-T cells operate in the absence of class I antigen presentation (TAPdeficiency) in contrast to naturally occurring CTL, as might be predicted from the mechanism of the CIR. CIR-T cells are therefore likely to be unaffected by such immune evasion strategies, although rapidly adaptive pathogens such as HIV-1 may still be able to escape through mutation of the recognized protein. In fact, CD4-independent strains of HIV-1 have been generated experimentally (Dumonceaux et al., 1998; Hoxie et al., 1998) , and these would potentially resist the activity of the CD4-CIR.
In the case of HIV-1, it appears that the Nef protein has an important role in rendering infected cells relatively resistant to the antiviral effects of CTL (Collins et al., 1998; Yang et al., 2002) . This is believed to be through the ability of Nef to downregulate the class I molecule from the cell surface (Collins et al., 1998) . We have found that Nef mediates viral resistance to suppression by naturally-derived CTL, but that CIR-CTL are unaffected and remain capable of inhibiting HIV-1 (Yang et al., 2002) . These data therefore confirm that CIR-CTL can entirely bypass the requirement for class I-restricted antigen processing and presentation, and can counteract immune evasion strategies such as that mediated by HIV-1 Nef.
Another important property for CTL to be effective is the ability to clear relevant cell types. For HIV-1, monocytes, myeloid dendritic cells, and dendritic cell/lymphocyte clusters are believed to be important sites of viral replication in vivo. The potentially important roles of monocyte/macrophages as long-lived viral reservoirs (Perelson et al., 1996) and myeloid dendritic cells as early transporters of virus in acute infection (Cameron et al., 1996; Grouard and Clark, 1997; Knight, 1996; Spira et al., 1996; Stahl-Hennig et al., 1999) prompted analysis of CIR-T cell activity on these cells. The ability of CIR-T cells to inhibit HIV-1 replication in all of these cell types indicates that gp120 expression on these cell types is adequate for recognition and viral control by CIR-T cells. Our previous work suggested that dendritic cell/lymphocyte clusters are less susceptible to the antiviral activity of HIV-1-specific CTL. CIR-T cells also appear to be less potent against these clusters. This indicates that the defect is not due to differences in antigen processing or presentation, but may be a consequence of the more vigorous rate of viral replication due to activation of lymphocytes by dendritic cells (Cameron et al., 1992; Pope et al., 1994) .
The capability of CIR-CTL to act on dendritic cells may have further implications in their immunotherapeutic application. Dendritic cells play a pivotal role in priming new CTL responses and providing immunologic help for the maintenance of immunity (Steinman and Inaba, 1999) . The ability of CIR-CTL to interact with dendritic cells suggests that it may be possible to use dendritic cells to activate and maintain transduced CIR-CTL.
In summary, we find that CIR-T cells may circumvent viral cellular immune evasion mechanisms relating to antigen presentation, and are capable of suppressing HIV-1 Fig. 2 . Suppression of HIV-1 replication in multiple CD4 ϩ primary cell types. Primary lymphocytes, monocytes, and dendritic cells were acutely infected with HIV-1 JR-CSF and cocultured with T3 or T3F3, and viral replication was monitored by p24 antigen measurement. These results are typical of four experiments comparing each cell type from two donors (data described in Results, and not shown). replication in monocytes, dendritic cells, and monocyte/ dendritic cell clusters. Thus, in comparison to naturallyderived specific CTL, CIR-T cells may be less susceptible to immune escape through mechanisms that interfere with class I antigen presentation, and are capable of acting upon multiple physiologic cell types.
Materials and methods
Immortalized target cells
HIV-1 permissive T cell lines used for acute infection included T1 cells, a CD4 ϩ lymphoblastoid cell line (Salter, et al., 1985) expressing HLA A2 (Yang et al., 1997a) , and T2 cells, a derivative of T1 cells deficient in transporter associated with processing complex (TAP) and therefore unable to transport antigens through the class I pathway (Salter and Cresswell, 1986) .
Primary target cells
Primary activated CD4 ϩ T lymphocytes, monocytes, and myeloid dendritic cells were generated from peripheral blood mononuclear cells as previously described (Severino et al., 2000) . In brief, lymphocytes were stimulated with a CD3:CD8 bispecific antibody (Wong and Colvin, 1987) , monocytes were isolated by adherence selection, and dendritic cells were produced by culture of monocytes in IL-4 and GM-CSF. The cell populations were confirmed by flow cytometry for CD3/CD4 (lymphocytes), CD14 (monocytes), and CD1a/CD80/CD86 (immature dendritic cells).
Effector cells
The RT-specific CTL clone 68A62 (specific for the HLA A2-restricted reverse transcriptase epitope ILKEPVHGV, derived from the PBMC of an infected person) and other HIV-1-specific CTL clones were maintained as previously described (Yang et al., 1997a) . T3F3 was derived by transduction of the CD8 ϩ primary T cell line T3 (isolated from the PBMC of an HIV-1-seronegative individual) with the CD4-construct (Roberts et al., 1994) .
HIV-1 suppression assays
The immortalized T cell lines or primary cells were acutely infected with HIV-1 IIIB or JR-CSF respectively, for co-culture assays with CTL as previously described (Severino et al., 2000; Yang et al., 1997a) . 5 ϫ 10 5 of the infected cells were cultured with 1.25 ϫ 10 5 effector cells in a 24 well plate in 2 ml of medium, followed by harvest of 1 ml for quantitative p24 antigen ELISA and medium replacement every two to four days. Prior control experiments indicated that suppression by naturally-derived CTL and T3F3 in this system is dose-dependent (not shown). Inhibi-tion after approximately 7 days of coculture in log 10 units was calculated by the formula: Ϫlog 10 (p24 with CTL/p24 without CTL).
Statistical comparisons
Student's t-test (two-tailed) was used to calculate P values for differences between groups (Excel, Microsoft Corporation).
